Loading
SY
Shanghai Yizhong Pharmaceutical Co., Ltd. Stock: price and insider trades · China
上海谊众
1 insider bought €14k of shares over the last 90 days, the latest by 周劲松, filed 30 Jul 2026.
Shanghai Yizhong Pharmaceutical Co., Ltd.: what insiders have been doing
Shanghai Yizhong Pharmaceutical Co., Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). In the past year (26 October 2025 to 26 October 2026), 1 filing came from 1 insider.
The flow runs one way only: 1 insider bought (1 purchase totalling €14k) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €14k, bought by 周劲松 and made public on 30 July 2026. The buyers include 1 board member.
With 1 filing in twelve months, the company is quieter than the median of 2 filings across the 515 companies we follow on the same exchange. The full history, which starts in 2023, counts 1 purchase against 10 sales.
The last insider purchase was made public on 30 July 2026, 88 days ago.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Insider Decl.
11
Thresholds
n/a
Buy Volume
€14,230
1 ops. · all time
Sell Volume
€17M
10 ops. · all time
Who traded when
BuySale刘刚5 sales
周劲松1 buy
球谊1 sale
Since the insiders bought
- -2.5%Entry CN¥36.68 · Close 13 Oct 2026 CN¥35.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,541 of 26,330 companies
54.8
score / 100
Value34
Quality76
FCF yld-1.9%
Earn yld0.8%
EV/EBITDA·
ROE4.7%
Gross mgn83%
Net mgn20%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥35.77
Analyst consensus
Income statement
RevenueCN¥316.1M
Gross profitCN¥262.7M83% margin
EBITDACN¥73.2M23% margin
Net incomeCN¥64.6M21.4% margin
Valuation
PER (trailing)105.2x
P/Book5.3x
Beta-0.44
Balance sheet & cash
Market capCN¥7.4B
Total debtCN¥25M
Free Cash Flow-CN¥149.5M
Debt / Equity2%
Profitability & ownership
ROE4.7%
ROA1.6%
% insiders52.5%
% institutions3.0%
Last declaration on 30 July 2026
Declarations11 total
3,000 shares@ CN¥284.5734100.0% of flowA股XSHGSSE:273000000904337100
Canonical exit: 28 Oct 2026 (T+90)
200 shares3.9% of flowA股XSHGSSE:173000009296171650
1,500 shares17.8% of flowA股XSHGSSE:173000008836355260
3,500 shares38.7% of flowA股XSHGSSE:173000008799471520
1,000 shares11.0% of flowA股XSHGSSE:173000008758952160
2,500 shares28.6% of flowA股XSHGSSE:173000008620034270
65,780 shares100.0% of flowA股XSHGSSE:173000008373349380
29,297 shares100.0% of flowA股XSHGSSE:173000007012332300
111,340 shares6.5% of flowA股XSHGSSE:173000006741139170
30,000 shares100.0% of flowA股XSHGSSE:173000006727434900
1,215,262 shares93.5% of flowA股XSHGSSE:173000006370659260
11 of 11 declarations
About Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong is a company operating in the healthcare and pharmaceutical sector, specializing in the research and development of pharmaceutical products. It is listed on the XSHG market.
